同仁堂国药(03613)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03613 同仁堂国药

休市中 11-06 16:08:52

5.775

+0.040

+0.70%

最高5.850	最低5.710	成交量158.60万
今开5.735	昨收5.735	日振幅2.44%
总市值48.34亿	流通市值48.34亿	总股本8.37亿
成交额918.55万	换手率0.19%	流通股本8.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03613","market":"HK","secType":"STK","nameCN":"同仁堂国药","latestPrice":5.775,"timestamp":1793952532006,"preClose":5.735,"halted":0,"volume":1586000,"delay":0,"changeRate":0.0069747166521360125,"floatShares":836999999,"shares":836999999,"eps":0.474514,"marketStatus":"休市中","change":0.04,"latestTime":"11-06 16:08:52","open":5.735,"high":5.85,"low":5.71,"amount":9185525,"amplitude":0.024412,"askPrice":5.775,"askSize":20000,"bidPrice":5.765,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":0.430713,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":7,"adr":0,"listingDate":1367856000000,"exchange":"SEHK","adjPreClose":5.735,"dividendRate":0.069281,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":2.081911263235896,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03613","defaultTab":"news","newsList":[{"id":"1135473294","title":"同仁堂国药更新10月股份变动月报表，股本维持837,100,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1135473294","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135473294?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:26","pubTimestamp":1793698003,"startTime":"0","endTime":"0","summary":"北京同仁堂国药有限公司（股票代码：03613）于2026年11月3日发布了截至2026年10月31日的股份变动月报表。该报告显示，公司截至当月末已发行股份总数为837,100,000股，与上月底数一致，库存股份依旧为0股，股本结构保持稳定。\n公告披露，公司在10月内无新增发行、购回或注销股份，也无任何库藏股变动或股份期权、股权激励计划变动。普通股仍在香港联合交易所上市，已发行股份及库存股份合计数与上月末相同。此外，公司确认有所需公众持股量符合相关监管要求。\n据公告，所有发行事宜均得到董事会正式授权并严格遵守相关法律及监管规则。该月报表由公司秘书曾凤仪签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146876095","title":"同仁堂国药披露控股股东业绩发布安排","url":"https://stock-news.laohu8.com/highlight/detail?id=1146876095","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146876095?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:21","pubTimestamp":1793352076,"startTime":"0","endTime":"0","summary":"2026年10月30日，同仁堂国药（03613）发布公告称，其控股股东同仁堂科技发展股份有限公司（01666）已于同日于香港交易所网站刊发截至2026年9月30日止九个月未经审计的财务信息。\n公告同时指出，同仁堂科技的控股股东北京同仁堂股份有限公司（600085）将于2026年10月31日或之前在上海证券交易所披露截至2026年9月30日止九个月未经审计的业绩。\n公司提醒股东及潜在投资者在买卖公司证券时务请审慎行事。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677481109","title":"ESMO年会开幕，创新药快速拉升，恒生生物科技指数翻红","url":"https://stock-news.laohu8.com/highlight/detail?id=2677481109","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677481109?lang=zh_cn&edition=full","pubTime":"2026-10-23 13:56","pubTimestamp":1792734960,"startTime":"0","endTime":"0","summary":"10月23日午后，港股三大指数集体拉升，恒生科技指数一度涨超2%，恒生国企指数、恒生指数跟涨；恒生生物科技指数午后翻红，亚盛医药、翰森制药、科伦博泰生物、先声药业、康方生物等盘中涨幅 ...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261023/c681018111.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261023/c681018111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["09926","00570","01666","02269","MEDX","BK1574","159992","02273","03759","LNGR","03737","06978","01643","06127","IBBQ","06606","BK1161","03613","06160","02359","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675455167","title":"【券商聚焦】中信证券：市场风格趋于谨慎 中药高股息标的关注度持续上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2675455167","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675455167?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:52","pubTimestamp":1792111979,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券表示，近期，市场风格趋于谨慎，中药高股息标的关注度持续上升。在此背景下，中药板块凭借\"低估值+高股息+成本端改善\"三重属性，成为具备高确定性的细分投资板块。该机构梳理两条投资主线：1）高股息率、业绩稳健标的。2）业绩边际向好、股息率具备一定吸引力的标的。风险因素：渠道库存积压的风险；业绩不及预期的风险；成本上涨的风险；集采不及预期的风险；重大支出后降低股息率的风险。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993818","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","LU1064131003.USD","PRIZ","LU1255011170.USD","BK0188","KCE","00570","LU0405327148.USD","02273","LU0405327494.USD","QUSA","02161","FTDS","06030","LU1997244956.HKD","03613","BK1570","00874","LU2580892789.USD","BK0012","PY","BK0276","BK1521","LU2148510915.USD","LU1146622755.USD","BK1516","BK1191","LU1328615791.USD","LU1720050803.USD","CGVV","159207","LU1794554557.SGD","LU1820825898.SGD","BK1564","02877","LU1064130708.USD","01643","LU1781817850.SGD","LU2289578879.USD","LU2580892862.HKD","BK0196","EASY","600030","LU1580142542.USD","03320","BK1147","BK1515","ABEQ","BK0183","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149261934","title":"同仁堂国药(03613)获准六款中成药在澳门销售 注册费用约5万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149261934","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149261934?lang=zh_cn&edition=full","pubTime":"2026-10-14 16:50","pubTimestamp":1791967858,"startTime":"0","endTime":"0","summary":"2026年10月14日，同仁堂国药有限公司发布自愿性公告称，其子公司北京同仁堂（澳门）有限公司已获澳门特别行政区政府药物监督管理局颁发《中成药注册证明书》，涉及六款中成药，可于澳门地区销售。截至公告日，公司为上述药品产生的相关注册费用合计约50,000港元，相关药品暂未在澳门销售。公司表示，上述注册证明书的取得有利于在澳门市场的拓展，但目前预计对生产经营和业绩无重大影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110840068","title":"同仁堂国药获批在港销售「定志丸」　增添中成药产品布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1110840068","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110840068?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:52","pubTimestamp":1791453166,"startTime":"0","endTime":"0","summary":"2026年10月8日，03613同仁堂国药发布自愿公告称，公司已获香港中医药管理委员会签发《中成药注册证明书》，准许其「定志丸」在中国香港地区销售。同仁堂国药披露，截至公告日，公司在该产品的研发投入累计约80万港元，目前尚未正式投放市场销售。公司表示，获得注册证明书后，「定志丸」可在香港销售，将有助于丰富产品线并支持市场拓展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194198252","title":"同仁堂国药发布2026年9月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1194198252","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194198252?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:46","pubTimestamp":1790930797,"startTime":"0","endTime":"0","summary":"同仁堂国药（股票代码：03613）于2026年10月2日公布了截至2026年9月30日的股份变动月报表。公告显示，公司上月底普通股已发行股份总数为837,100,000股，且无库存股份；在报告期内不存在新增发行、购回、注销或持作库存的情况。截至本月底，公司普通股已发行股份总数继续保持837,100,000股不变，股本结构稳定。\n此外，公告提及在报告期内，公司无已发行的股份期权、权证或可换股票据等方面的变动信息。公司并在报告中确认，已遵守香港联合交易所有限公司《上市规则》和其他适用法律法规的要求。\n本次公告由公司秘书曾凤仪签署。公司表示，将继续密切关注并依据监管要求履行信息披露义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174352391","title":"同仁堂国药2026年中期财报营收6.02亿港元，经调整净利润1.98亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174352391","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174352391?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:57","pubTimestamp":1789376228,"startTime":"0","endTime":"0","summary":"同仁堂国药发布2026年中期业绩公告。报告期内，公司实现营收6.02亿港元，同比下降21.0%。经调整净利润为1.98亿港元，同比下降15.6%。毛利率由上年同期的60.8%提升至63.9%。经营现金流为2.73亿港元，较上年同期的4.80亿港元有所减少。公司在报告期内持续优化成本结构，销售及分销费用约为1.00亿港元，相比上年同期的1.03亿港元有所下降；一般及行政支出也从上年同期的0.89亿港元降至0.83亿港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"同仁堂国药2026年中期财报营收6.02亿港元，经调整净利润1.98亿港元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191836054","title":"同仁堂国药8月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1191836054","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191836054?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:36","pubTimestamp":1788255374,"startTime":"0","endTime":"0","summary":"北京同仁堂国药有限公司（股票代码：03613）于2026年9月1日发布2026年8月31日止的证券变动月报表。报告期为2026年8月，当月公司已发行股份总数为837,100,000股，与上个月底数一致，库存股份数量为0。\n公告显示，报告期内公司未发生新增发行、购回、注销或库藏股变动。公司确认已符合香港联交所相关公眾持股量的规定并遵守了适用的上市规则及相关法律法规要求。本次月报由公司秘书曾凤仪签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663078029","title":"港股异动 | 同仁堂国药(03613)跌超8% 上半年纯利同比减少15.6% 收入下跌超两成","url":"https://stock-news.laohu8.com/highlight/detail?id=2663078029","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663078029?lang=zh_cn&edition=full","pubTime":"2026-08-31 11:23","pubTimestamp":1788146608,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同仁堂国药跌超8%，截至发稿，跌8.38%，报5.955港元，成交额2753.59万港元。消息面上，同仁堂国药公布2026年中期业绩，上半年实现收入约6.02亿港元，同比减少21%；公司拥有人应占利润约1.98亿港元，同比减少15.6%。公告称，毛利率从去年同期60.8%上升至本期内 63.9%，同比增长3.1%，同时，利润跌幅小于收入跌幅，表明公司在成本费用管控与产品结构优化方面的努力持续见效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK1191","BK4588","BK1606","VXUS","03613","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662406706","title":"同仁堂国药(03613.HK)与同仁堂数字科技订立电商服务合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2662406706","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662406706?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:42","pubTimestamp":1787917361,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1606","03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662067123","title":"同仁堂国药(03613)公布中期业绩 拥有人应占利润约1.98亿港元 同比减少15.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662067123","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662067123?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:32","pubTimestamp":1787916772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同仁堂国药(03613)公布2026年中期业绩，收入约6.02亿港元，同比减少21%;公司拥有人应占利润约1.98亿港元，同比减少15.6%;每股盈利0.24港元。公告称，毛利率从去年同期60.8%上升至本期内 63.9%，同比增长3.1%，同时，利润跌幅小于收入跌幅，表明公司在成本费用管控与产品结构优化方面的努力持续见效。本期内，资金结构保持稳健，经营现金流充裕，有息负债极低，财务缓冲能力充足;同时，存货金额持续下降，资产配置进一步向核心业务聚焦，整体资产结构得到持续优化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03613","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130652106","title":"同仁堂国药获批在港销售「三子养亲颗粒」 注册证书有效期至2031年","url":"https://stock-news.laohu8.com/highlight/detail?id=1130652106","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130652106?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:24","pubTimestamp":1787916282,"startTime":"0","endTime":"0","summary":"北京同仁堂国药有限公司8月28日发布自愿公告称，公司近日收到香港中医药管理委员会颁发的《中成药注册证明书》，批准将「三子养亲颗粒」在中国香港特别行政区销售。该药品注册编号为HKC-18820，证书有效期至2031年8月25日。公司表示，凭借本次获批的注册证明书，「三子养亲颗粒」可在香港销售，将有助于丰富公司产品线并支持市场拓展。公司提醒股东及潜在投资者，于买卖公司证券时须审慎行事。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184963284","title":"同仁堂国药（03613）与同仁堂数字科技签署电商服务新框架协议 最高年度交易上限900万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184963284","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184963284?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:24","pubTimestamp":1787916242,"startTime":"0","endTime":"0","summary":"2026年8月28日， 同仁堂国药公告披露，已于当日交易时段后与同仁堂数字科技有限公司签订《电商服务合作框架协议》。根据协议，同仁堂数字科技集团将在2026年8月28日至2028年12月31日期间，为同仁堂国药集团成员的“同仁堂”品牌产品在“京东”“天猫”“抖音”等电商渠道提供运营管理、咨询及产品营销等服务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187773730","title":"同仁堂国药2026年中期营收6.02亿港元，经调整净利润1.98亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187773730","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187773730?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:12","pubTimestamp":1787915535,"startTime":"0","endTime":"0","summary":"同仁堂国药公布的2026年中期报告显示，期内实现营收6.02亿港元，同比下降21.0%；经调整净利润1.98亿港元，同比下降15.6%。毛利为3.85亿港元，同比下降16.9%，但毛利率从上年同期的60.8%上升至63.9%。经营利润率约为35.8%，经营活动产生的现金净额为2.73亿港元，同比减少43.2%。销售及分销开支同比下降2.3%，一般及行政开支同比下降6.8%。报告称，公司继续加强中医药国际化推广，围绕安宫牛黄丸等核心产品在多个海外市场推进注册备案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"同仁堂国药2026年中期营收6.02亿港元，经调整净利润1.98亿港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119353746","title":"同仁堂国药（03613）拟于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1119353746","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119353746?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:25","pubTimestamp":1786699530,"startTime":"0","endTime":"0","summary":"北京同仁堂国药有限公司（03613）8月14日公告称，公司董事会将于2026年8月28日（星期五）召开会议，拟审议截至2026年6月30日止六个月之中期业绩，并考虑派发股息（如有）。\n公告同时披露，董事会成员包括：  \n1. 执行董事：严晗（主席）、乐拯（副主席）、王驰  \n2. 非执行董事：冯莉  \n3. 独立非执行董事：曾钰成、徐宏喜、陈毅驰\n公司表示，将在董事会会议后及时公布相关决议及中期业绩报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174891210","title":"同仁堂国药更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1174891210","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174891210?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:56","pubTimestamp":1785833778,"startTime":"0","endTime":"0","summary":"北京同仁堂国药有限公司（股票代码：03613）于2026年8月4日公布了截至2026年7月31日的证券变动月报表。报告显示，期末普通股已发行股份（不包括库存股份）总数为837,100,000股，与上月底持平。公司当月无新增发行、回购、注销或库藏股变动。\n本报告期内，无股份期权、权证、可换股票据或其他股权激励计划相关股份变动，公司已发行股本结构未发生调整。公司确认已遵守香港联交所《上市规则》及相关法律法规的所有要求。\n本次公告由公司秘书曾凤仪签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651584492","title":"【券商聚焦】光大证券：议优先布局经营稳健、业绩扎实或者股息类中药标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2651584492","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651584492?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:54","pubTimestamp":1784163265,"startTime":"0","endTime":"0","summary":"金吾财讯 | 光大证券研究指，近期，中药板块持续上涨，主要受到市场避险、政策利好、业绩催化和估值底部等多重因素共同推动，中期配置价值显著，后市偏乐观。建议优先布局经营稳健、业绩扎实或者高股息类中药标的。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985990","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","02877","BK1147","BK1521","BK1564","02273","01643","03320","BK1197","KCE","BK1191","02161","00874","VIG","BK0276","BK0183","BK0188","BK1515","BK1570","BK1219","BK4585","BK4588","601788","BK0012","BK0028","06178","00570","03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149021920","title":"同仁堂国药6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149021920","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149021920?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:02","pubTimestamp":1783069348,"startTime":"0","endTime":"0","summary":"同仁堂国药（股票代码：03613）于2026年7月3日提交的公告显示，截至2026年6月30日，公司总股本未发生变化。\n根据公告，公司的普通股已发行股份数量在6月末为837,100,000股，与上月末持平，库存股份数为0股，报告期内未发生新增发行、回购或注销，也未披露任何股份期权、可换股票据、权证或股权激励计划的变动。公司确认其公众持股量持续符合香港联交所《上市规则》的相关要求。\n公告同时说明，所有应向公司收取的发行款项已完成或正在进行中，公司严格遵守了香港联交所《上市规则》及相关法律法规的要求。本次月报表由公司秘书曾凤仪签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190826094","title":"同仁堂国药5月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1190826094","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190826094?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:43","pubTimestamp":1780476180,"startTime":"0","endTime":"0","summary":"北京同仁堂国药有限公司于2026年6月3日发布截至2026年5月31日的证券变动月报表。本次月报显示，公司普通股本月底结存为837,100,000股，与上月结存的837,100,000股保持一致；库存股份数目依旧为0股，表明在本报告期内公司未新增发行股份、也无任何购回、注销或库存股票的变动。报告同时显示，公司无新增股份期权或股权激励计划变化，未发生可转换债券、新增权证及其他发行协议相关的股份变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tongrentangcm.com","stockEarnings":[{"period":"1week","weight":0.0221},{"period":"1month","weight":0.0567},{"period":"3month","weight":-0.1342},{"period":"6month","weight":-0.1771},{"period":"1year","weight":-0.3019},{"period":"ytd","weight":-0.2763}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京同仁堂国药有限公司是一家主要从事生产和销售中药业务的投资控股公司。该公司通过三个分部运营业务。香港分部从事在香港透过零售店铺销售中药产品及保健品，提供中医诊断服务，以及批发中药产品。其还从事管理使用“同仁堂”品牌的海外实体缴纳的品牌使用费业务。中国内地分部在中国内地批发保健品，以及在非中国内地客户独家分销同仁堂科技及同仁堂股份的同仁堂品牌产品。海外分部在其他海外国家零售及批发中药产品和保健品，并提供中医诊疗服务业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.020119},{"month":2,"riseRate":0.5,"avgChangeRate":0.026054},{"month":3,"riseRate":0.625,"avgChangeRate":-0.004309},{"month":4,"riseRate":0.625,"avgChangeRate":0.03756},{"month":5,"riseRate":0.25,"avgChangeRate":-0.015206},{"month":6,"riseRate":0.333333,"avgChangeRate":0.031207},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.052069},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.028811},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.041098},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.056742},{"month":11,"riseRate":0.777778,"avgChangeRate":0.052047},{"month":12,"riseRate":0.5,"avgChangeRate":0.046725}],"exchange":"SEHK","name":"同仁堂国药","nameEN":"TONGRENTANGCM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同仁堂国药(03613)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同仁堂国药(03613)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同仁堂国药,03613,同仁堂国药股票,同仁堂国药股票老虎,同仁堂国药股票老虎国际,同仁堂国药行情,同仁堂国药股票行情,同仁堂国药股价,同仁堂国药股市,同仁堂国药股票价格,同仁堂国药股票交易,同仁堂国药股票购买,同仁堂国药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同仁堂国药(03613)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同仁堂国药(03613)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}